3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
4
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
19
Breast Neoplasms
12
Lung Neoplasms
10
Brain Neoplasms
9
Glioblastoma
7
Neoplasm Metastasis
6
Neoplasms
5
Glioma
5
Carcinoma, Renal Cell
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Pancreatic Neoplasms
4
Head and Neck Neoplasms
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Mycosis Fungoides
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Liver Neoplasms
3
Gliosarcoma
3
Waldenstrom Macroglobulinemia
2
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Sezary Syndrome
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neuroendocrine Tumors
2
Interventions
obinutuzumab
1
ioflupane
1
idelalisib
1
daratumumab
1
alovudine
1
Vindesine
1
Vincristine
1
Rituximab
1
Prednisone
1
Positron Emission Tomography Computed Tomography
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Ga(III)-DOTATOC
1
Doxorubicin
1
Dexamethasone
1
Cyclophosphamide
1
Bleomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT00633958
2021-10-20
FLT
Dana-Farber Cancer Institute
Phase 1
Terminated
2 enrolled